[Construction of recombinant vaccinia virus co-expressing mutant E6 plus E7 proteins and detection of its immunogenicity and antitumor response].
OBJECTIVE
To generate a candidate HPV16 vaccine for experimental and therapeutical use for cervical cancer.


METHODS
The mutants of HPV16 early E6 and E7 genes were inserted into a vaccinia virus expression vector. A strain of recombinant vaccinia virus was constructed through homologous recombination.


RESULTS
Showed that the mutant E6 and E7 genes were located at TK gene region of vaccinia virus Tiantan strain in a head to head orientation under the control of early/late promoters, H6 and 7.5K respectively. Studies in mice indicated that VmE6E7 could elicit specific antibodies against E6 and E7, and retarded or prevented tumor development in a proportion of C57 BL/6 mice challenged by syngeneic HPV16E6 and E7 transformed tumor cells.


CONCLUSIONS
The success in constructing VmE6E7 provides a basis for the further development of HPV16 therapeutic vaccine.
Zhi
Huijun
H
Institute of Virology, Chinese Academy of Preventive Medicine, Beijing 100052, China.
Han
Liqun
L
Ren
Jiao
J
Tian
Houwen
H
Luo
Weifeng
W
Liang
Yu
Y
Ruan
Li
L
D000818:Animals; D005260:Female; D005814:Genes, Viral / Q000235:genetics*; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009154:Mutation; D009374:Neoplasms, Experimental / Q000517:prevention & control*; D009856:Oncogene Proteins, Viral / Q000235:genetics*; D027383:Papillomaviridae / Q000235:genetics*; D050725:Papillomavirus E7 Proteins; D011995:Recombination, Genetic; D012097:Repressor Proteins; D014162:Transfection; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology*
C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins; C059731:oncogene protein E7, Human papillomavirus type 16